MX2016011982A - Prediccion in vitro de semivida in vivo de anticuerpos. - Google Patents
Prediccion in vitro de semivida in vivo de anticuerpos.Info
- Publication number
- MX2016011982A MX2016011982A MX2016011982A MX2016011982A MX2016011982A MX 2016011982 A MX2016011982 A MX 2016011982A MX 2016011982 A MX2016011982 A MX 2016011982A MX 2016011982 A MX2016011982 A MX 2016011982A MX 2016011982 A MX2016011982 A MX 2016011982A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- fcrn
- life
- vivo half
- retention time
- Prior art date
Links
- 238000001727 in vivo Methods 0.000 title abstract 3
- 238000000338 in vitro Methods 0.000 title 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 4
- 230000014759 maintenance of location Effects 0.000 abstract 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 abstract 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 abstract 2
- 238000001042 affinity chromatography Methods 0.000 abstract 2
- 238000010828 elution Methods 0.000 abstract 2
- 230000003993 interaction Effects 0.000 abstract 2
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
- B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
- B01D15/166—Fluid composition conditioning, e.g. gradient
- B01D15/168—Fluid composition conditioning, e.g. gradient pH gradient, chromatofocusing, i.e. separation according to the isoelectric point pI
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
Abstract
En este documento se reporta un método para determinar la presencia de una interacción de Fab de anticuerpo-FcRn en un complejo de Fc de anticuerpo-FcRn que incluye en semivida in vivo comprende los pasos que consisten en a) determinar el tiempo de retención del anticuerpo en una columna de cromatografía de afinidad por FcRn con una elución con gradiente de pH lineal positivo en presencia de una primera concentración de cloruro de sodio, y b) determinar el tiempo de retención del anticuerpo en una columna de cromatografía de afinidad por FcRn con una elución con gradiente de pH lineal positivo en presencia de una segunda concentración de cloruro de sodio, con lo cual la presencia de una interacción de Fab de anticuerpo-FcRn en un complejo de Fc de anticuerpo-FcRn que influye en la semivida in vivo se determina si el tiempo de retención determinado en el paso a) y el tiempo de retención determinado en el paso b) son sustancialmente diferentes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14161103 | 2014-03-21 | ||
| EP14165987 | 2014-04-25 | ||
| PCT/EP2015/055482 WO2015140126A1 (en) | 2014-03-21 | 2015-03-17 | In vitro prediction of in vivo half-life of antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016011982A true MX2016011982A (es) | 2016-12-09 |
Family
ID=52684232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011982A MX2016011982A (es) | 2014-03-21 | 2015-03-17 | Prediccion in vitro de semivida in vivo de anticuerpos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20170227547A1 (es) |
| EP (1) | EP3119490B1 (es) |
| JP (2) | JP6744855B2 (es) |
| KR (1) | KR20160134687A (es) |
| CN (1) | CN106103478B (es) |
| BR (1) | BR112016023417A2 (es) |
| CA (1) | CA2938722A1 (es) |
| MX (1) | MX2016011982A (es) |
| RU (1) | RU2688349C2 (es) |
| WO (1) | WO2015140126A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102069397B1 (ko) | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Ｆｃ-수용체 기재 친화성 크로마토그래피 |
| MX2016002720A (es) * | 2013-09-06 | 2016-06-08 | Hoffmann La Roche | Metodo para mejorar la estabilidad del anticuerpo. |
| CA2960797A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| CN106957365B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb8及其应用 |
| CN106957364B (zh) * | 2016-01-11 | 2021-03-16 | 上海交通大学 | 一种单克隆抗体FnAb12及其应用 |
| WO2018197533A1 (en) | 2017-04-28 | 2018-11-01 | F. Hoffmann-La Roche Ag | Antibody selection method |
| US20200047085A1 (en) * | 2018-08-09 | 2020-02-13 | Regeneron Pharmaceuticals, Inc. | Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor |
| EP3861026A1 (en) | 2018-10-01 | 2021-08-11 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising anti-fap clone 212 |
| JP2022511396A (ja) | 2018-10-01 | 2022-01-31 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｃｄ４０への三価結合を伴う二重特異性抗原結合分子 |
| JP2022512798A (ja) * | 2018-10-25 | 2022-02-07 | エフ．ホフマン－ラ ロシュ アーゲー | 抗体ＦｃＲｎ結合の改変 |
| JPWO2020116560A1 (ja) * | 2018-12-05 | 2021-10-21 | 株式会社バイカ・セラピュティクス | 抗体のＦｃ領域改変体 |
| EP3903102B1 (en) | 2018-12-30 | 2023-04-12 | F. Hoffmann-La Roche AG | Ph-gradient spr-based binding assay |
| AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| JP7322858B2 (ja) * | 2020-11-02 | 2023-08-08 | 株式会社三洋物産 | 遊技機 |
| JP7322857B2 (ja) * | 2020-11-02 | 2023-08-08 | 株式会社三洋物産 | 遊技機 |
| CN113308476B (zh) * | 2021-05-12 | 2022-06-28 | 广东药康生物科技有限公司 | 一种FcRn基因人源化动物模型的构建方法 |
| JPWO2022244838A1 (es) * | 2021-05-19 | 2022-11-24 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004290070A1 (en) * | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto |
| KR101862402B1 (ko) * | 2011-12-06 | 2018-05-30 | 삼성전기주식회사 | 도체 패턴 및 이를 포함하는 코일 부품 |
| KR102069397B1 (ko) * | 2012-02-15 | 2020-01-22 | 에프. 호프만-라 로슈 아게 | Ｆｃ-수용체 기재 친화성 크로마토그래피 |
-
2015
- 2015-03-17 MX MX2016011982A patent/MX2016011982A/es active IP Right Grant
- 2015-03-17 CN CN201580015172.9A patent/CN106103478B/zh active Active
- 2015-03-17 RU RU2016137932A patent/RU2688349C2/ru active
- 2015-03-17 KR KR1020167025760A patent/KR20160134687A/ko not_active Application Discontinuation
- 2015-03-17 BR BR112016023417-0A patent/BR112016023417A2/pt not_active Application Discontinuation
- 2015-03-17 JP JP2017500408A patent/JP6744855B2/ja active Active
- 2015-03-17 EP EP15710178.3A patent/EP3119490B1/en active Active
- 2015-03-17 CA CA2938722A patent/CA2938722A1/en not_active Abandoned
- 2015-03-17 WO PCT/EP2015/055482 patent/WO2015140126A1/en active Application Filing
-
2016
- 2016-09-20 US US15/271,091 patent/US20170227547A1/en not_active Abandoned
-
2020
- 2020-07-31 JP JP2020129979A patent/JP7032490B2/ja active Active
-
2021
- 2021-01-26 US US17/158,431 patent/US20210190795A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016023417A2 (pt) | 2019-04-16 |
| RU2016137932A (ru) | 2018-04-23 |
| CN106103478A (zh) | 2016-11-09 |
| US20170227547A1 (en) | 2017-08-10 |
| JP2020183967A (ja) | 2020-11-12 |
| EP3119490A1 (en) | 2017-01-25 |
| JP2017517745A (ja) | 2017-06-29 |
| CA2938722A1 (en) | 2015-09-24 |
| JP7032490B2 (ja) | 2022-03-08 |
| JP6744855B2 (ja) | 2020-08-19 |
| RU2016137932A3 (es) | 2018-10-29 |
| EP3119490B1 (en) | 2021-09-08 |
| KR20160134687A (ko) | 2016-11-23 |
| US20210190795A1 (en) | 2021-06-24 |
| RU2688349C2 (ru) | 2019-05-21 |
| CN106103478B (zh) | 2020-04-03 |
| WO2015140126A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011982A (es) | Prediccion in vitro de semivida in vivo de anticuerpos. | |
| MX2020009021A (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifarmaco. | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| BR112019007714A2 (pt) | anticorpos de 4-1bb anti-humanos e usos dos mesmos | |
| JOP20190283B1 (ar) | طريقة لتصنيع أجسام مضادة ثنائية النوعية، والأجسام المضادة ثنائية النوعية والاستخدام العلاجي لها | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| NZ714079A (en) | Purification process for monoclonal antibodies | |
| MX2018001536A (es) | Metodo para la reduccion de proteinas de celulas hospederas en cromatografia de afinidad. | |
| MX2016011809A (es) | Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y metodos de produccion y uso de los mismos. | |
| EA201690213A1 (ru) | Композиции и способ лечения связанных с комплементом состояний | |
| TW201612189A (en) | Sterile chromatography and manufacturing processes | |
| MX2016013991A (es) | Metodo y sistema para determinacion de humectabilidad resuelta espacialmente. | |
| EA202091989A1 (ru) | Способы лечения язвенного колита | |
| MX2019001572A (es) | Método de cromatografía para cuantificar un tensioactivo no iónico en una composición que comprende el tensioactivo no iónico y un polipéptido. | |
| CU20160008A7 (es) | Métodos para controlar los niveles de fucosilacion en proteinas | |
| MX2023008870A (es) | Composiciones y metodos para reducir la carga biologica en cromatografia. | |
| TR201818966T4 (tr) | İyon değişim kromatografisi girdi optimizasyonunun açıklaması. | |
| SE1751327A1 (en) | System and method for optical inspection of an object | |
| MX363679B (es) | Metodo para diagnosticar cancer. | |
| EP3734282A4 (en) | DEVICE, REAGENT KIT AND METHOD FOR DETECTION OF MISFOLDED PROTEIN | |
| EA201790725A1 (ru) | Основанные на близости расположения способы выбора партнеров для связывания | |
| MX2015015023A (es) | Metodo para la determinacion de cobre libre. | |
| MY192159A (en) | Method for detecting neutralizing antibodies against recombinant human insulin in human serum | |
| SG10201810877TA (en) | Method for determining a protein-protein interaction | |
| MX2018005834A (es) | Separacion de proteina mejorada en cromatografia de intercambio de ion. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |